04:02
Dr. Amy DeZern on Peripheral Blood Mutation Correlations With Bone Marrow in MDS
08:28
How Do Home Socioeconomic Environment Factors Affect SCD Care for Patients?
08:40
Dr. Surbhi Sidana Presents Real-World Data Supporting Cilta-Cel for Multiple Myeloma
07:27
Assessing the State of Stroke Risk, Prevention in Patients With SCD
03:43
Dr. Diesch-Furlanetto on Fertility Considerations With Hydroxyurea in SCD
08:51
Dr. Naik on the ASH Hematology-Focused Fellowship Training Program
04:58
Academic Mentorships Invigorate the Classical Hematology Profession
07:19
Dr. Nausheen Ahmed on the Need to Monitor Infection Risk After CAR-T Therapy
06:40
Dr. Steven Romano on Promising Small Interfering RNA Compound Results in PV
01:36
How Do Clinicians Choose Pharmacotherapy for Lower-Risk MDS?
02:42
How Have the COMMANDS Trial Data Changed Lower-Risk MDS Care?
03:19
The Need to Address Nonmalignant Afflictions in Hematology Nursing
02:12
Solly Chedid, MD, Describes the Landscape of Upcoming MDS Agents
07:56
How Can the Transition From Pediatric to Adult Care in SCD Be Optimized?
07:59
Dr. Restrepo: Current Coagulopathy Risk Screening in Venous Malformations May Be Flawed
12:37
EHA President-elect Dr. Döhner On the 'Lighting the Flame' Program
06:36
Akhila Vadivelan, MD, Discusses Iron Deposition in Transfusion-Dependent SCD
01:49
Yaw Ansong-Ansongton, MD, Highlights National Minority Health Month, Celebrate Diversity Month
02:22
Erica Mamauag, MD, Finds That FVIII May Be Unnecessary in Tolerized Hemophilia A
03:55
Yaw Ansong-Ansongton, MD, on the Impact of Abnormal Mitochondria in Sickled Red Blood Cells
11:57
Anjali Sharathkumar, MD, Shares Romiplostim Outcomes in Severe Aplastic Anemia With MDS
04:08
Zaina Inam, MD, on Transplant Outcomes in Pediatric Patients With SCD
09:26
Real-world Analysis of Pegcetacoplan in PNH with Hemolysis
02:26
Michael Grunwald, MD, Highlights Polycythemia Vera for Rare Disease Day
03:46
Zahra Pakbaz, MD, on the Challenges of Hematology Patients Swapping From Pediatric to Adult Programs
07:06
How Does SCD Impact Brain Growth in Infants?
04:23
Zahra Pakbaz, MD, John Strouse, MD, PhD, Discuss Practicing Classical Hematology
05:25
Zahra Pakbaz, MD, Describes the Value of a Dedicated Classical Hematology Clinic
06:05
Zahra Pakbaz, MD, Defines the Unmet Need for Specialists in Adult Classical Hematology
05:07
Gabriela Hobbs, MD, Discusses Updated Data on Ruxolitinib Use During, After Transplant
05:53
Panel Predicts the Future for Myelodysplastic Syndromes: Treatment, Sequencing, and Research
05:27
Patient-Reported Outcomes, Quality of Life for Luspatercept Versus Epoetin Alfa in MDS
03:41
Biomarker Analysis on Inflammatory Effect for Luspatercept Versus Epoetin Alfa in Patients with MDS
05:20
Real-World Outcomes of Non-Transfusion-Dependent Patients with MDS Treated with Luspatercept
04:29
Impact of Molecular Characteristics and Response to Luspatercept in Patients with MDS
05:54
Implications of the Full Analysis of the COMMANDS Trial of Luspatercept for MDS
05:09
Evolving MDS Treatment Options and the MEDALIST Trial
04:27
Myelodysplastic Syndromes: Overview, Diagnosis, Therapy, and More
06:40
Haydar Frangoul, MD, Details CLIMB-121 Data on Exa-cel in Sickle Cell Disease
05:14
ASH 2023 Data and Impacts on MDS Care: Molecular Markers, New Treatment Options, MRD
04:14
Can Early Transplant Be Used for Patients with Low-Risk MDS?
05:29
Panel Discusses New Data on Emerging Therapies in MDS: Imetelstat, KER-050, and More
03:03
Real-World Quality of Life, Patient Experience Associated with Luspatercept
06:55
Panel Shares Thoughts on Luspatercept for MDS and Future Research Needs for This Therapy
06:17
Mutational Status, Comorbidities and MDS Treatment Selection
06:35
Panel Reacts to Full Analysis of the COMMANDS Trial of Luspatercept for MDS
02:49
What Are the Treatment Options for Patients with Low-Risk Myelodysplastic Syndromes?
04:04
Lucia Masarova, MD, on Transfusion-Related Cost Findings From Simplify-1
X
About
Tags